Carmencita Lanez, MD
Psychiatry · Perth Amboy, NJNPI 1770643959
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,400 of the $49,199 with a category attached, or 74.0%. AbbVie accounts for 82.3% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $12,374 and has fallen 54.0% since, to $5,690 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 934 payments — averaging $52.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$40K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Sunovion Pharmaceuticals Inc.$1K
- Alkermes, Inc.$603
- Neurocrine Biosciences, Inc.$571
- plus $4K from 25 others
What the payments were for
- Speaking & faculty fees$36,40074%
- Travel & lodging$1,2503%
- Food & beverage$11,54923%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 313 | $40,480 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 102 | $1,336 |
| Otsuka America Pharmaceutical, Inc. | 88 | $1,195 |
| Sunovion Pharmaceuticals Inc. | 73 | $1,096 |
| Alkermes, Inc. | 36 | $603 |
| Neurocrine Biosciences, Inc. | 36 | $571 |
| Lundbeck LLC | 46 | $523 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $512 |
| Axsome Therapeutics, Inc. | 25 | $381 |
| Jazz Pharmaceuticals Inc. | 21 | $293 |
| Tris Pharma Inc | 19 | $288 |
| Rhodes Pharmaceuticals L.p. | 19 | $263 |
| Supernus Pharmaceuticals, Inc. | 17 | $257 |
| Vanda Pharmaceuticals Inc. | 18 | $255 |
| Corium, LLC | 18 | $206 |
| Teva Pharmaceuticals USA, Inc. | 13 | $204 |
| E.r. Squibb & Sons, L.L.C. | 7 | $115 |
| Bausch Health US, LLC | 7 | $114 |
| Ironshore Pharmaceuticals Inc. | 7 | $102 |
| Collegium Pharmaceutical, Inc. | 5 | $75 |
| Neos Therapeutics, LP | 5 | $65 |
| OWP Pharmaceuticals, Inc. | 4 | $56 |
| Johnson & Johnson | 2 | $33 |
| Validus Pharmaceuticals LLC | 2 | $31 |
| Adlon Therapeutics L.p. | 2 | $29 |
| Shire North American Group Inc | 2 | $27 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| Sage Therapeutics, LLC | 1 | $18 |
| Neuronetics, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$37,653
- LYBALVI$403
- ABILIFY MAINTENA$120
- ABILIFY ASIMTUFII$120
How this compares
$49,199 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 18 | $144,894 |
| Invega SustennaPaliperidone Palmitate | 25 | $61,540 |
| VraylarCariprazine Hcl | 38 | $56,579 |
| RexultiBrexpiprazole | 22 | $35,360 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,286 |
| Divalproex Sodium ErDivalproex Sodium | 196 | $9,191 |
| Aripiprazole | 119 | $8,803 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 117 | $7,285 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 381 | $7,198 |
| Bupropion XlBupropion Hcl | 163 | $5,340 |
| Lisdexamfetamine Dimesylate | 25 | $4,670 |
| Quetiapine Fumarate | 221 | $4,248 |
| Clozapine | 29 | $3,382 |
| Vilazodone Hcl | 21 | $3,067 |
| Escitalopram Oxalate | 319 | $2,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $571 | $144,89418 claims |
| Johnson & JohnsonInvega Sustenna | $33 | $61,54025 claims |
| AbbVieVraylar | $40,480 | $56,57938 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,195 | $35,36022 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $512 | $13,28636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Perth Amboy
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
- Boris BorodulinEast Brunswick$116K
- Anthony RostainCamden$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.